Neurodegenerative Diseases
152
36
44
60
Key Insights
Highlights
Success Rate
92% trial completion (above average)
Published Results
11 trials with published results (7%)
Research Maturity
60 completed trials (39% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
3.3%
5 terminated out of 152 trials
92.3%
+5.8% vs benchmark
5%
7 trials in Phase 3/4
18%
11 of 60 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 60 completed trials
Clinical Trials (152)
Decision-making, Ethical Consent, and Interactive Dialogue in Ongoing Neurocognitive Decline - DECISION
A Phase 3 Study of NTLA-2001 in ATTRv-PN
A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)
A Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of Inflammation
Novel Technologies to Measure Vision-related Quality of Life
Hereditary Spastic Paraplegia Genomic Sequencing Initiative (HSPseq)
Study on the Application of ¹⁸F-FCOB04, a MAO-B Targeted PET Imaging Agent, in Neurodegenerative Diseases
Allopregnanolone Regenerative Therapeutic for Mild Alzheimer's Disease
NAD+ Oral Supplement Pilot Intervention in Adult Females
An Open-Label Extension of XPro1595 in Patients With Alzheimer's Disease
Kamlanoflast In Amyotrophic Lateral Sclerosis
Continuation Study for Latozinemab
Slowing Cognitive Decline in Alpha-synucleinopathies by Enhancing Physical Activity
Normal Chinese Lifespan Brain Charts Initiative (NCLBCI)
Validation of the VIRADIA App for Neurological and Cognitive Diagnostics in Virtual Reality
Evaluation of the Peripheral Nerve Ultrasound as a Diagnostic Tool in CANVAS Neuropathies
Development and Test of a Headset for BCI Until Obtaining an Efficient and Comfortable System That Can be Used in Daily Practice by ALS People
Clinical Research on Stem Cell Therapy for Parkinson's Disease
A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)
Cognitive Reserve and Response to Speech-Language Intervention in Bilingual Speakers With Primary Progressive Aphasia